Incyte Patent-Cliff Exposure & CMS Drug Spending Portfolio

Incyte (Wilmington, DE): 6 reconciled FDA prescription therapies (98.6% 2025 to 2030 cliff risk), $2.51B 2024 CMS Part D & Medicaid spend, and 18 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterWilmington, DE
Reconciled FDA Portfolio Therapies6
2025 to 2030 Patent-Cliff Revenue Exposure98.6%
Primary Portfolio LOE Date2029-01-01
2024 CMS Total Public Spend$2.51B
2024 Medicare Part D Spend$2.22B
2024 Medicaid Spend$291.2M
California HCAI SB 17 Filings18 WAC filings (max 20.0% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Incyte across sibling Meru public-data platforms.